StemRIM (4599.T)

475.00 +2.00 (+0.42%) At close: 03:15PM JST

StemRIM

Saito Bio-Incubator
3rd Floor 7-7-15, Saito-Asagi
Ibaraki 567-0085
Japan
81 72 648 7152
https://www.stemrim.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 45

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kensuke Tomita	Executive Chairman	21M	N/A	1949
Mr. Masatsune Okajima	President, CEO & Representative Director	30M	N/A	1968
Mr. Katsuto Tamai	Chief Scientific Officer, Director of Basic Research Department & Director	N/A	N/A	1960
Mr. Takehiko Yamazaki	Head of Drug Discovery, Basic Research, R&D and Intellectual Prop., Dept. and Executive Officer	N/A	N/A	1970

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in JPY.

Description

StemRIM, a biotechnology company, develops regeneration medicines for the treatment of intractable diseases. The company develops PJ1, a regeneration induction medicine HMGB1 peptides, which is in Phase II clinical trials for the treatment of epidermolysis bullosa, cerebral infarction, osteoarthritis, and chronic liver disease, as well as cardiomyopathy. Its pre-clinical stage products include PJ2 and PJ3 to treat multiple tissue damage disease; PJ4, an autologous cell sampling device for medical treatment; and PJ5, a stem cell gene therapy. StemRIM was incorporated in 2006 and is based in Ibaraki, Japan.

Corporate governance

StemRIM’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.